@article{CCO22621,
author = {Cristina Cristofoletti and Maria Grazia Narducci and Giandomenico Russo},
title = {Sézary syndrome, recent biomarkers and new drugs},
journal = {Chinese Clinical Oncology},
volume = {8},
number = {1},
year = {2018},
keywords = {},
abstract = {Sezary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. In this context, we discuss the major malignancy-related biomarkers reported in the literature for the diagnosis, prognosis and staging of SS. The hope for a single reliable diagnostic marker appears increasingly unrealistic, but the discovery of multiple potential biomarkers, with pathogenetic implications, paves the road to promising personalized therapies in SS.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/22621}
}